March 29, 2022 -- Biotechnology company Ichnos Sciences will present preclinical data for ISB 1442, a bispecific antibody, at the American Association for Cancer Research (AACR) annual meeting, held April 8-13, 2022.
ISB 1442 is currently being investigated in blood cancers, including relapsed/refractory multiple myeloma, T cell acute lymphoblastic leukemia, and acute myeloid leukemia. The company said that enrollment in the first-in-human ISB 1442 trial is expected to start in mid-2022.
The poster is titled "ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38+ malignancies" (2903/18).
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
